Patents Issued in January 21, 2020
-
Patent number: 10537566Abstract: The present invention relates to combinations and pharmaceutical compositions comprising siponimod and laquinimod, and the use of said combinations and/or compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.Type: GrantFiled: October 14, 2015Date of Patent: January 21, 2020Assignee: Novartis AGInventor: Paul Alfred Smith
-
Patent number: 10537567Abstract: Disclosed are therapeutic compositions including BA-1076 and/or BA-2057, methods of their use in the treatment of ophthalmological disorders. The therapeutic compositions may further include an IOP-lowering prostaglandin. The methods may further include administration of an IOP-lowering prostaglandin.Type: GrantFiled: July 11, 2018Date of Patent: January 21, 2020Assignee: BioAxone BioSciences, Inc.Inventors: Joerg Ruschel, Matthew D. Abbinanti, Kenneth M. Rosen, Lisa McKerracher
-
Patent number: 10537568Abstract: The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. The combination can be useful during and following radiation exposure to ameliorate the inflammatory response.Type: GrantFiled: December 18, 2015Date of Patent: January 21, 2020Assignee: IRR, Inc.Inventor: Bruce Chandler May
-
Patent number: 10537569Abstract: The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.Type: GrantFiled: December 22, 2016Date of Patent: January 21, 2020Assignees: ALZPROTECT, Universite de Lille 2 Droit et Saute, Inserm (Institut National De La Saute et de la Recherche MedicaleInventors: Stéphane Burlet, Cécilia Estrella, Mathieu Barrier, Patricia Melnyk, Nicolas Sergeant, Luc Buee, Philippe Verwaerde
-
Patent number: 10537570Abstract: The invention relates to pimobendan for use in a method of reducing the heart size and/or delaying the onset of clinical symptoms in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), and/or delaying the onset of heart failure, preferably congestive heart failure, in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), wherein the patient is preferably a mammal, more preferably a human, a dog, a cat or a horse, and most preferably a dog.Type: GrantFiled: April 3, 2017Date of Patent: January 21, 2020Inventors: Christoph Schummer, Olaf Joens
-
Patent number: 10537571Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.Type: GrantFiled: June 20, 2017Date of Patent: January 21, 2020Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
-
Patent number: 10537572Abstract: The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.Type: GrantFiled: April 19, 2018Date of Patent: January 21, 2020Assignee: AbbVie Inc.Inventors: Sandra L. Goss, Cheri E. Klein, Juki Wing-Keung Ng, Ahmed Salem
-
Patent number: 10537573Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.Type: GrantFiled: January 20, 2015Date of Patent: January 21, 2020Assignee: Janssen Pharmaceutica NVInventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Roger Francis Bone
-
Patent number: 10537574Abstract: This disclosure relates to the use of kinase inhibitor to treat or prevent infectious diseases such as tuberculosis. In certain embodiments, this disclosure relates to treating or preventing an infectious disease comprising administering an effective amount of a kinase inhibitor or other compound disclosed herein to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing tuberculosis comprising administering a kinase inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with Mycobacterium tuberculosis (Mtb) that is resistant to multiple antibiotic agents.Type: GrantFiled: September 16, 2016Date of Patent: January 21, 2020Assignee: Emory UniversityInventor: Daniel Kalman
-
Patent number: 10537575Abstract: The present disclosure concerns the use of a phosphodiesterase inhibitor, such as, for example, sildenafil, to repair a brain and/or a retinal injury in a newborn. The phosphodiesterase inhibitor can be used in a premature or a term baby that has been exposed to hyperoxia or hypoxia which caused a brain and/or a retinal injury.Type: GrantFiled: July 31, 2017Date of Patent: January 21, 2020Inventor: Pia Wintermark
-
Patent number: 10537576Abstract: Methods of treating breast cancer are provided where a quantitative Her2 assay is used to identify whether a breast tumor will be responsive to treatment with anti-Her2 therapeutic agents such as lapatinib and trastuzumab, followed by selection of a suitable treatment regimen and administration of the regimen. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in breast tumor cells collected from breast tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the breast cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.Type: GrantFiled: December 9, 2016Date of Patent: January 21, 2020Assignee: Expression Pathology, Inc.Inventors: Adele Blackler, Todd Hembrough, Fabiola Cecchi, Paolo Nuciforo
-
Patent number: 10537577Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.Type: GrantFiled: November 2, 2017Date of Patent: January 21, 2020Assignees: Emory University, The United States Government as represented by the Department of Veterans AffairsInventors: Scott D. Boden, Sreedhara Sangadala
-
Patent number: 10537578Abstract: This disclosure pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). Also disclosed resulting (high purity) compounds, compositions comprising them (e.g.Type: GrantFiled: September 28, 2017Date of Patent: January 21, 2020Inventors: John Mervyn David Storey, James Peter Sinclair, Colin Marshall, Han Wan Tan, Claude Michel Wischik
-
Patent number: 10537579Abstract: To provide a novel method for suppressing rejection after corneal transplantation. The method for suppressing rejection after corneal transplantation includes administering an effective amount of a Rho kinase inhibitor to a patient who needs it.Type: GrantFiled: May 10, 2018Date of Patent: January 21, 2020Assignees: JUNTENDO EDUCATIONAL FOUNDATION, KOWA COMPANY, LTD.Inventors: Takenori Inomata, Toshinari Funaki
-
Patent number: 10537580Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.Type: GrantFiled: December 20, 2017Date of Patent: January 21, 2020Assignee: NOVIRA THERAPEUTICS, INC.Inventors: George D. Hartman, Scott Kuduk
-
Patent number: 10537581Abstract: According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.Type: GrantFiled: October 22, 2014Date of Patent: January 21, 2020Assignee: TherapeuticsMD, Inc.Inventors: Brian A. Bernick, Thorsteinn Thorsteinsson, Peter H. R. Persicaner, Janice Louise Cacace, Frederick D. Sancilio, Neda Irani, Julia Amadio
-
Patent number: 10537582Abstract: A method for contraception includes administering to a female daily, in a fourphasic dosing regimen during a time period of 24 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein doses in the second, third and fourth phases of the regimen increase by a predefined dose increment as compared to the corresponding doses administered during the previous phase, wherein the norethindrone acetate dose in the first phase is 1000 mcg, in the second phase is 1125 mcg, in the third phase is 1250 mcg, and in the fourth phase is 1375 mcg, wherein the EE dose in the first phase is 20 mcg, in the second phase is 22.5 mcg, in the third phase is 25 mcg, and in the fourth phase is 27.5 mcg, and wherein the fourphasic dosing regimen is followed by 4 days without norethindrone acetate and EE administration.Type: GrantFiled: June 3, 2019Date of Patent: January 21, 2020Assignee: ARSTAT, INC.Inventor: Arkady Rubin
-
Patent number: 10537583Abstract: An oral formulation, and preparation method and use thereof; the oral formulation comprises 1-50 parts by weight of an A-nor-5a-androstane compound, 20-95 parts by weight of a filling agent, 0-20 parts by weight of a disintegrant, 0.1-30 parts by weight of a binder, 0.1-5 parts by weight of a lubricant and 0.1-5 parts by weight of a glidant. The oral formulation has a high stability and a good dissolution performance.Type: GrantFiled: September 28, 2015Date of Patent: January 21, 2020Inventor: Yajun Chen
-
Patent number: 10537584Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.Type: GrantFiled: June 8, 2016Date of Patent: January 21, 2020Assignee: FERRING B.V.Inventors: Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
-
Patent number: 10537585Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: December 18, 2017Date of Patent: January 21, 2020Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.Inventors: Caterina Kreyenborg, Elisabeth Meimberg, Corinna Tissen, Karl-Heinz Bannefeld, Tomer Gold
-
Patent number: 10537586Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.Type: GrantFiled: January 18, 2019Date of Patent: January 21, 2020Assignee: POP TEST ONCOLOGY LLCInventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
-
Patent number: 10537587Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.Type: GrantFiled: September 6, 2018Date of Patent: January 21, 2020Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.Inventor: Wei He
-
Patent number: 10537588Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.Type: GrantFiled: January 9, 2018Date of Patent: January 21, 2020Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
-
Patent number: 10537589Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.Type: GrantFiled: February 10, 2017Date of Patent: January 21, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
-
Patent number: 10537590Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and R3 are defined as in claim 1, which have valuable pharmacological properties, particularly are modulators of STING.Type: GrantFiled: September 27, 2017Date of Patent: January 21, 2020Assignee: Boehringer Ingelheim International GmbHInventors: Thorsten Oost, Sebastian Carotta, Martin Fleck
-
Patent number: 10537591Abstract: The invention solves the problem of providing new therapies that are effective in the treatment of muscular dystrophies through the use of compositions comprising a compound capable of reducing the expression of miRNA-106b in muscle satellite stem cells of a human or animal subject with respect to the expression observed in the absence of the compound in said cells.Type: GrantFiled: May 12, 2016Date of Patent: January 21, 2020Assignee: UNIVERSIDAD DE JAENInventors: Amelia Eva Aranega Jimenez, Diego Franco Jaime, Francisco Hernandez Torres, Estefania Lozano Velasco, Daniel Vallejo Pulido
-
Patent number: 10537592Abstract: The disclosure relates to decarboxylated cannabis resins and methods of making the decarboxylated cannabis resins by extraction and decarboxylation of cannabinoids from Cannabis species using microwaves and solvents. The disclosure also relates to use of the decarboxylated cannabis resins for making pharmaceutical products comprising same.Type: GrantFiled: July 17, 2019Date of Patent: January 21, 2020Assignee: CannScience Innovations Inc.Inventors: Lakshmi Premakanth Kotra, Melissa Maureen Lewis, Ewa Wasilewski, Har Grover
-
Patent number: 10537593Abstract: Provided are a method, target and application for NO accumulation to decrease invasiveness of Pseudomonas aeruginosa; achieving NO accumulation by means of external NO donors or disruption of internal NO metabolism in an environment where Pseudomonas aeruginosa is growing or being cultured, in order to decrease production by Pseudomonas aeruginosa of the invasion factor pyocyanin. Utilizing even micro-quantities of NO can significantly inhibit Pseudomonas aeruginosa PCN (PCN synthesis down 82% with 60 ?M SNP treatment); by inhibiting NO reductase, an enzyme related to NO metabolism, PCN synthesis can be significantly inhibited (the PAO1-?nor strain has 84% PCN reduction). Using NO donors or inhibiting enzymes involved in Pseudomonas aeruginosa NO metabolism as a means of combating bacterial infectious disease does not affect the body's normal microflora like traditional antibiotics.Type: GrantFiled: October 22, 2016Date of Patent: January 21, 2020Inventors: Yi Wan, Chang Chen, Lei Gao, Yuying Zhang, Xinhua Qiao, Yan Wang
-
Patent number: 10537594Abstract: The present disclosure relates to, inter alia, compositions and kits comprising an asialoglycoprotein covalently attached to a polycation, and functional mammalian mitochondria that are at least partially purified and are electrostatically bound to the AsG-polycation molecule; as well as methods of their preparation and use.Type: GrantFiled: February 26, 2016Date of Patent: January 21, 2020Assignee: University of ConnecticutInventors: George Y Wu, Catherine H Wu, Nidhi Gupta
-
Patent number: 10537595Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.Type: GrantFiled: November 15, 2018Date of Patent: January 21, 2020Assignee: Iovance Biotherapeutics, Inc.Inventors: Seth Wardell, James Bender, Michael T. Lotze
-
Patent number: 10537596Abstract: The embodiments disclosed herein generally relate to systems, devices and methods for the fractionation, isolation, extraction and processing of the adipose supernatant layer of a bone marrow aspirate. In particular, the various embodiments relate to systems devices and methods of obtaining, utilizing and processing the adipose supernatant layer of a bone marrow aspirate as a source of mesenchymal stem cells.Type: GrantFiled: April 20, 2018Date of Patent: January 21, 2020Assignee: Regenexx LLCInventors: Christopher Centeno, Ryan Dregalla, Nicolette Lyons, Patrick Reischling
-
Patent number: 10537597Abstract: The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.Type: GrantFiled: October 5, 2016Date of Patent: January 21, 2020Assignee: Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In DavosInventors: Liam O'Mahony, Cezmi A. Akdis, David Michalovich, Edith M. Hessel, James R. Brown, David N. Mayhew, Sorif Uddin
-
Patent number: 10537598Abstract: The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strains capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.Type: GrantFiled: January 23, 2019Date of Patent: January 21, 2020Assignees: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY, BIOGAIA ABInventors: Eamonn Connolly, Robert Allen Britton, Laura Rae McCabe
-
Patent number: 10537599Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.Type: GrantFiled: December 2, 2016Date of Patent: January 21, 2020Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Linde Miles, John Poirier, Charles Rudin
-
Patent number: 10537600Abstract: The present invention relates to a traditional Chinese medicine composition for regulating immunity and preparation method thereof, characterized in that the composition comprises raw materials such as Radix Panacis Quinquefolii, Ganoderma, fermented Cordyceps sinensis powder, Flos Rosae Rugosae, and Rhizoma Anemarrhenae and is prepared into various conventional pharmaceutical formulations through processes such as pulverization, water decoction and alcohol extraction. The traditional Chinese medicine composition is effective in preventing and treating allergic diseases, hepatitis B and AIDS, elevating leukocytes, preventing and treating radiation injury, reducing toxic and side effects resulting from radiotherapy and chemotherapy, improving the male sexual function, enhancing immunity of the human body and alleviating physical fatigue.Type: GrantFiled: September 7, 2017Date of Patent: January 21, 2020Assignee: JIANGZHONG PHARMACEUTICALS CO., LTD.Inventors: Hongguang Zhong, Minzhi Yi, Jianzhong Lu
-
Method of isolating anti-viral ingredients from , compositions comprising them and their medical use
Patent number: 10537601Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.Type: GrantFiled: April 4, 2016Date of Patent: January 21, 2020Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Jing-Rong Wang, Zhi-Hong Jiang, Qi-Tong Feng, Guo-Yuan Zhu, Wei-Na Gao, Zifeng Yang, Nanshan Zhong -
Patent number: 10537602Abstract: A fish feed includes carvacrol and/or salvia extract (provided that where the fish feed comprises carvacrol and not salvia extract the lipid content of the fish feed is at least 15 wt %). The salvia extract may be selected from extract of Salvia officinalis and extract of Salvia lavandulifolia. The carvacrol may be synthetic or may be extracted from Origanum vulgare.Type: GrantFiled: March 6, 2019Date of Patent: January 21, 2020Assignee: NUTRECO IP ASSETS B.V.Inventors: Wolfgang Koppe, Alex Obach, Ramon Fontanillas
-
Patent number: 10537603Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.Type: GrantFiled: May 21, 2015Date of Patent: January 21, 2020Assignee: Korea Institute of Oriental MedicineInventors: Jin Sook Kim, Junghyun Kim, Chan-Sik Kim, Eunjin Shon, Yun Mi Lee, Young Sook Kim, Sojin Choi, Ik Soo Lee, Dong Ho Jung, Bo-Jeong Pyun, Seung-Hyun Jung
-
Patent number: 10537604Abstract: A method for enhancing at least one of alertness, attention, concentration and memory in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b).Type: GrantFiled: July 19, 2016Date of Patent: January 21, 2020Assignee: NEKTIUM PHARMA, S.L.Inventors: Miguel Jimenez del Rio, Julia C. Wiebe, Laura Lopez-Rios, Tanausu Vega-Morales, Ruben Perez-Machin, Alvaro Sanchez-Rodriguez, Carlos Mateos, Nigel Peter Gericke
-
Patent number: 10537605Abstract: Provided is a plant extract composition and a pharmaceutical composition thereof for reducing body weight and body fat, wherein the plant extract composition comprises a green tea extract and a turmeric extract respectively 30 wt % to 75 wt % and 20 wt % to 55 wt % of a total weight of the composition. In diet-induced obesity models, either obesity is induced first or simultaneously with administration, the plant extract composition and a pharmaceutical composition thereof can reduce body weight and body fat more significantly than a single plant extract or commercially available weight loss drugs.Type: GrantFiled: August 28, 2015Date of Patent: January 21, 2020Assignee: CALIWAY BIOPHARMACEUTICALS CO., LTD.Inventor: Yu-Fang Ling
-
Patent number: 10537606Abstract: The present disclosure relates to a formulation for preventing and treating cancer which avoids the undesirable side effects observed when using the conventional therapies. The formulation in accordance with the present disclosure comprises a formulation having active constituents comprising a combination of extracts from Boswellia spp, Curcuma longa and Vitis vinifera.Type: GrantFiled: January 6, 2015Date of Patent: January 21, 2020Assignee: OMNI CURE LTD.Inventors: Jatin Thakkar, Gisli Örn Lárusson
-
Patent number: 10537607Abstract: Provided herein are novel compositions, specifically, caveolin modulators, and methods to treat and/or prevent autoimmune and/or inflammatory diseases/conditions using such compositions.Type: GrantFiled: November 21, 2014Date of Patent: January 21, 2020Assignee: E&B Technologies LLCInventors: David Eveleth, William C. Sessa
-
Patent number: 10537608Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.Type: GrantFiled: August 14, 2017Date of Patent: January 21, 2020Assignee: ALLYSTA PHARMACEUTICALS, INC.Inventor: Henry Hsu
-
Patent number: 10537609Abstract: Pseudomonas aeruginosa flagellin protein recruits the mammalian host sialidase enzyme neuraminidase-1 (NEU1) to remove sialic acid residues from the extracellular domain of the mammalian cell-surface protein MUC1 (MUC1-ED), thereby exposing a cryptic binding site on the MUC1-ED protein backbone for flagellin binding. NEU1-driven MUC1-ED desialylation rapidly increases P. aeruginosa adhesion to the airway epithelium. MUC1-ED desialylation also increases MUC1-ED cleavage and shedding from the cell surface, where desialylated, shed MUC1-ED competitively blocks P. aeruginosa adhesion to cell-associated MUC1-ED. Presented herein are data showing that exogenously-administered, deglycosylated MUC1-ED peptides reduced adhesion of P. aeruginosa to airway epithelial cells. Also presented are data showing that administration of P. aeruginosa to mice in combination with deglycosylated MUC1-ED decreased P. aeruginosa recovered from the lungs at 48 hr and 72 hr post-infection.Type: GrantFiled: June 22, 2017Date of Patent: January 21, 2020Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Erik P. Lillehoj, Avelino C. Verceles, Simeon E. Goldblum
-
Patent number: 10537610Abstract: Methods for treating breast cancer, the methods can include administering to a subject an effective amount of a cell adhesion molecule Receptor (F11R peptide).Type: GrantFiled: October 24, 2018Date of Patent: January 21, 2020Inventors: Anna Babinska, Radoslaw Bednarek, Elizabeth Kornecki, Moro O. Salifu, Yigal H. Ehrlich, Maria Swiatkowska, Cristina C. Clement
-
Patent number: 10537611Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.Type: GrantFiled: June 8, 2018Date of Patent: January 21, 2020Assignee: Five Prime Therapeutics, Inc.Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
-
Patent number: 10537612Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 24, 2015Date of Patent: January 21, 2020Assignee: Eisai R&D Management Co., Ltd.Inventors: Ryo Ohori, Kanta Horie
-
Patent number: 10537613Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.Type: GrantFiled: January 18, 2018Date of Patent: January 21, 2020Assignee: The Medical College of Wisconsin, Inc.Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
-
Patent number: 10537614Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a corticosteroid and exosomes. By means of the combination therapy diseases such as osteoarthritis, arthritis and/or degenerative spinal diseases can be treated.Type: GrantFiled: June 12, 2017Date of Patent: January 21, 2020Assignee: ORTHOGEN AGInventors: Peter Wehling, Julio Reinecke
-
Patent number: 10537615Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.Type: GrantFiled: March 14, 2018Date of Patent: January 21, 2020Assignee: Altor Bioscience, LLCInventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong